Kornimate/medical-research-clean huggingface dataset:
prophylaxis of exposed covid-19 individuals with mild symptoms using choloroquine compounds

Conditions: Sars-CoV2; Symptomatic Condition; Covid-19

Summary: to treat pakistani patients with non-life threatening symptomatic sars-cov-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling sars-cov-2 infection.


Eligibility criteria:
inclusion criteria: 1. symptomatic patients: defined as fever (temperature greater than 100 degree f), cough, or shortness of breath (respiratory rate \>22 per minute). 2. nasopharyngeal rt-pcr positive sars-cov-2 3. age 20-50 years 4. bmi 18-28 kg/m2 5. informed consent exclusion criteria: 1. o2 saturation by pulse-oximeter below 93% 2. co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes 3. arrhythmias and/or history of arrythmia 4. psoriasis and/or history of psoriasis 5. neuropathy or myopathy and/or history of these 6. hypoglycemia and/or history of hypoglycemia 7. pre-existing hepatic disease 8. pre-existing renal disease 9. use of antacids within 1 week 10. use of antiobiotics within 1 week 11. pregnancy 12. rt-pcr performed \>7 days prior to enrollment
evaluation of the effect of adding dexamethasone to 2% lidocaine

Conditions: Pulpitis - Irreversible

Summary: this randomized, double-blind clinical trial aimed at the evaluation of the effect of adding dexamethasone to 2% lidocaine, given as inferior alveolar nerve block in the endodontic management of symptomatic irreversible pulpitis. one hundred and twenty four patients received one of the three ianb injections before the endodontic treatment: 2% lidocaine with 1:80 000 epinephrine; 2% lidocaine with 1:80 000 epinephrine mixed with 2mg dexamethasone; and plain 2% lidocaine mixed with 2mg dexamethasone. the anesthetia was considered successful if the patients experienced no pain or faint/weak/mild pain during root canal access preparation and instrumentation (hp vas score \<55 mm). the effect of intraligamentary injections on maximum heart rates was also recorded.


Eligibility criteria:
inclusion criteria: * absence of any periapical radiolucency on radiographs, except for a widened periodontal ligament * active pain in a mandibular molar * prolonged response to cold testing with an ice stick and an electric pulp tester * vital coronal pulp on access opening and ability to understand the use of pain scales exclusion criteria: * a history of known or suspected drug abuse * history of active peptic ulcer within the preceding 12 months * history of bleeding problems or anticoagulant use within the last month * known allergy, sensitivity, or contraindications to any opioid or nonopioid analgesic including aspirin or nsaids * patients who had taken nsaids within 12 h before administration of the study drugs * patients who were pregnant or breast-feeding
pharmacological intervention in depression after traumatic brain injury

Conditions: TBI (Traumatic Brain Injury)

Summary: the purpose of this study is to determine if treatment with venlafaxine reduces symptoms of depression in persons with traumatic brain injury.

the study evaluates the benefits of a promising antidepressant medication for the treatment of persons with traumatic brain injury (tbi) and major depressive disorder (mdd). the study is a randomized, double-blind, placebo-controlled trial of venlafaxine (a serotonin and norepinephrine reuptake inhibitor, also known as effexor). venlafaxine has been well established in the treatment of mdd in healthy individuals and is a recommended depression treatment agent for persons with tbi. by using a rigorous scientific methodology, this study will be an important first step in advancing the treatment of depression in this population beyond general impressions to proven treatments.

Eligibility criteria:
inclusion criteria: * must have a documented traumatic brain injury (tbi), defined as damage to brain tissue caused by an external mechanical force as evidenced by: loss of consciousness due to brain trauma, or post traumatic amnesia (pta), or skull fracture, or objective neurological findings that can be reasonably attributed to tbi on physical examination or mental status examination. * age 18 years or older * at least three months postinjury * presence of major depressive disorder (mdd), as defined by structured clinical interview for dsm-iv (scid) interview * hamilton depression rating scale (ham-d) scores of 18 or greater on two consecutive evaluations (screening and baseline) exclusion criteria: * individuals under 18 years of age * pregnancy, as determined by urine pregnancy screen * prisoners * individuals who are institutionalized * individuals who are not cognitively capable of completing the scid interview and the ham-d * unstable medical condition, defined as any significant medical condition likely to require hospitalization during the study period, or requiring adjustment in medications in the past month * active suicidality * severe depression that, in the investigator's professional opinion, will likely require hospitalization during the study time period * diagnosis of bipolar disorder, as defined by scid interview * diagnosis of schizophrenia or other psychotic disorder, as defined by scid interview, other than major depression with psychotic features * active drug or alcohol abuse within the past 3 months, as defined by scid interview * dysphagia sufficient to preclude use of oral medications * known hypersensitivity to venlafaxine * use of monamine oxidase inhibitors (maoi) within the past month * treatment with antidepressant medication within the past 3 months * concomitant administration of medications that interact with venlafaxine to a clinically significant degree

Keywords: depression after brain injury traumatic brain injury venlafaxine
monitoring asthma treatment using exhaled nitric oxide

Conditions: Asthma

Summary: asthma is a chronic inflammatory condition in which the airways develop increased responsiveness to various stimuli such as exposure to an allergen, cold air or exercise. it is characterized by airway hyper-responsiveness, inflammation, increased mucus production, and airway obstruction. since inflammation is an important feature of asthma, the use of non-invasive tests to measure lung inflammation to monitor asthma are of interest.the purpose of the study is to relate costs associated with healthcare utilization and loss of work and school time to the primary health outcome of cumulative number of symptom-free days. this will enable the researchers to determine whether the costs of monitoring exhaled no to regular management strategy in recently diagnosed asthma will be offset by reductions in other costs of asthma-related care, and, if not, whether the additional costs are likely to be acceptable in terms of the improvement in health outcomes as measured by the additional number of symptom-free days.


Eligibility criteria:
inclusion criteria: * male or female children, aged 6-14 years * a documented history of asthma for a period of at least 6 months * mild to severe persistent asthma according to gina guidelines * a documented history of allergic sensitization (positive skin prick test or specific ige * subject's guardian/parent should be able to complete a symptom score on behalf of the subject. * subject's guardian/parent should be able to send a symptom score weekly by sms * both parents have to give written informed consent to participate in the study exclusion criteria: * received any investigational study medication in the 4 weeks prior to screening visit * significant comorbidity such as concurrent infection, history of prematurity, history of bronchopulmonary dysplasia, cystic fibrosis, other chronic lung diseases, and other severe chronic diseases * acute asthma exacerbation within 4 weeks of screening visit * hospitalization within 12 weeks of screening visit * systemic corticosteroids within 12 weeks of screening visit * oral corticosteroid dependence

Keywords: exhaled no asthma child
lithovue single use disposable ureteroscope

Conditions: Kidney Stone

Summary: most flexible ureteroscopes that are used to treat kidney stones have been reusable. recently, advances in technology have resulted in single-use (disposable) ureteroscopes to become available. the investigators are interested in determining if the performance of the two types of scopes are equivalent. this will help guide institutions in the future to purchase the best scopes for their patients.

ureteroscopy is commonly used in the treatment of kidney stones. flexible ureteroscopes are costly to purchase and repair. issues with flexible ureteroscopes include loss of deflection and visual performance (fiberoptic pixels) with use and the high repair costs. reprocessing and sterilization of reusable ureteroscopes also requires staff who are specially trained and dedicated in this area. inadequate sterilization could also lead to transmissible infections between patients. a single-use flexible digital ureteroscope has recently become commercially available (lithovue, boston scientific, marlborough, ma). pre-clinical testing show the accessibility to the ureter and all areas of the kidney to be equivalent to current flexible ureteroscopes. however, clinical data comparing this single-use ureteroscope to a current state of the art reusable ureteroscope is lacking. establishing at least equivalence in performance between the new single use ureteroscope and a reusable digital ureteroscope will help surgeons and operating room managers/administrators help determine how to most efficiently equip their operating rooms with endoscopic equipment.

Eligibility criteria:
inclusion criteria: * patients scheduled for ureteroscopy and laser lithotripsy for individual renal stones ranging in size from 5 mm to 20 mm in all intrarenal locations (if there are multiple stones present, the total stone burden in cross section should not exceed 20 mm) * 19 years or older and able to provide informed consent exclusion criteria: * patients \< 18 years * pregnant * patients with known nephrocalcinosis . * any other reason that in the opinion of the investigator would make the participant unsuitable for enrollment in the study.

Keywords: ureteroscopy lithovue nephrolithiasis single use ureteroscope
acceptability, feasibility and preliminary impact of ourplan, an mhealth hiv prevention intervention for male couples

Conditions: HIV/AIDS

Summary: the study will evaluate the use and preliminary impact of an mhealth app for improving sexual health outcome measures among male couples by assessing whether exposure and use of the app results in improvements in participants and couples' self-reported sexual health and prevention behaviors, beliefs, and attitudes. the study will enroll both men of the couple into a randomized controlled trial. participants/couples randomized to the intervention will have access to the app for two months while those assigned to the waitlist group will receive and have access to the app for one month. participants will complete surveys at baseline and at month 2.

the study will evaluate the use and preliminary impact of an mhealth app for improving sexual health outcome measures among male couples by assessing whether exposure and use of the app results in improvements in participants and couples' self-reported sexual health and prevention behaviors, beliefs, and attitudes. the study will enroll both partners of the 42 male couples into a 2-month randomized controlled trial with a waitlist control condition of one month. couples will be assigned to either the immediate intervention group ("intervention arm") or the waitlist-control group ("waitlist-control arm"). all participants will take an assessment survey at baseline, and the intervention group will be oriented on the installation and use of the app upon randomization to that group. the waitlist-control group will follow the same procedures one month later. participants/couples randomized to the intervention arm will have access to the intervention app for two months (ie, day 1-60) while those assigned to the waitlist-control group will have access to the app for one month (ie, day 31-60). all participants in the randomized controlled trial will complete a short follow-up survey at month 2 and a brief exit interview.

Eligibility criteria:
inclusion criteria for both partners of the male couple: * self-reported that currently self-identifies as a male * self-reported in a sexual relationship with another self-identified male * self-reported relationship length between 1 and 12 months * self-reported anal sex with relationship partner in past 2 months * owns and uses an internet-connected smartphone or tablet * resides in the u.s. * self-reported ability to read and understand english-language exclusion criteria: * does not meet one or more the inclusion criteria
self-weighing: an ecological momentary assessment

Conditions: Daily Self-weighing; Daily Temperature-taking

Summary: the primary objective of this study is to experimentally test the momentary and more distal psychological effects of daily self weighing as compared to an active control group.

two significant public health problems, obesity and eating disorders, are prevalent during emerging adulthood, a unique stage of life between ages 18 and 25. over half of emerging adults experience weight gain and/or disordered eating (e.g. overly restrictive dieting, binge eating); both of which contribute to obesity. because many emerging adults attend college, the college community represents a viable population for implementing interventions to prevent weight gain, while not triggering disordered eating. a promising strategy for preventing weight gain during college is daily self-weighing, an example of behavioral self-monitoring, an evidence-based strategy for weight control. self-monitoring is fundamental to behavior change: feedback allows the user to evaluate progress in relation to a goal and modify behavior. despite self-monitoring being recommended, some evidence suggests that self-monitoring strategies, self-weighing in particular, may have unintended psychological consequences; the concern being that negative mood states could precipitate disordered eating. alternatively, other evidence suggests positive psychological outcomes related to daily self-weighing in young adults. technological advances have allowed for users to track personal health information in real time. given that 60% of u.s. adults track weight, diet, or exercise, and 92% of adults aged 18-34 own a smartphone, electronic self-monitoring is feasible in this population. what is less known is individuals' psychological and behavioral response to self-monitoring. this original, important study will contribute to the fields of obesity and eating disorders and experimentally test the psychological effects of this daily weight-control intervention.

Eligibility criteria:
inclusion criteria: * female * between the ages of 18 and 26 * ud student * owns a smart phone * if participant does not currently have an eating disorder or has never had one in the past exclusion criteria: * if participant currently has an eating disorder or has had one in the past * if participant answers "yes" to 3 or more items in scoff

Keywords: self-weighing weight gain ecological momentary assessment mood emerging adulthood obesity eating disorders
evaluation of efficacy of ophthalmic solution in seasonal allergic conjunctivitis

Conditions: Allergic Conjunctivitis

Summary: the purpose of this summary is to evaluate the efficacy and safety of r89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis


Eligibility criteria:
inclusion criteria: * history of positive diagnostic test for ragweed within the past 2 years; * positive bilateral response to ragweed as induced by conjunctival allergen challenge exclusion criteria: * ocular infection; * history of retinal detachment, diabetic neuropathy, or any progressive retinal disease; * moderate to severe asthma; * dry eye syndrome; * history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal or autoimmune disease; * pregnancy or lactation

Keywords: allergic conjunctivitis, ophthalmology, multicenter, controlled
long term follow-up study of immuncell-lc group and non-treatment group in hepatocellular carcinoma patients.

Conditions: Hepatocellular Carcinoma

Summary: to observation that long term follow-up study of 'immuncell-lc groups' and 'non-treatment groups' in patient undergo curative resection (peit, rfa or operation) for hepatocellular carcinoma in korea


Eligibility criteria:
inclusion criteria: * prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent. * patients of participated in the(clinicaltrials.gov identifier:nct00699816)clinical trial. exclusion criteria: * patient who is incongruent to this clinical trial by sub-investigator's opinion.

Keywords: immuncell-lc, hepatocellular carcinoma
evaluation of marginal integrity of hydroxyapatite nano-fiber reinforced flowable composite versus conventional resin-based flowable composite in initially demineralized pits and fissure: a one year, randomized clinical trial

Conditions: Marginal Integrity of Hydroxyapatite Nanofiber Reinforced Flowable Composite

Summary: this study will be conducted to evaluate the marginal integrity of hydroxyapatite nanofiber reinforced flowable composite compared to a conventional resin-based flowable composite during management of initial carious lesion in adult population over a one year period.

a total of 26 volunteer patients with at least 2 non-cavitated molar teeth will be assigned in this study. patients will be divided into two groups according to type of flowable composite (r) where groups r1 the pits and fissure will be sealed with hydroxyapatite nanofiber reinforced flowable composite while groups r2 the pits and fissure will be sealed with conventional resin-based flowable composite. each restoration will be assessed after one week, six and twelve months both materials will be applied according to manufacturer's instructions where teeth should be cleaned to remove surface stains, then select appropriate shade of the flowable composite, a rubber dam is the preferred method of isolation, etch and rinse adhesive system is applied, where acid etching will be applied for 15 seconds then rinse and dry followed by application of adhesive then light cure 10 seconds, then place and cure in 2 mm increments of the flowable composite for 20 s., gently remove oxygen inhibition layer after light cure with slurry of pumice or polishing paste all restorations were reviewed after 1 week, 6, 12 months by two investigators who were blinded to the material used for the restorations. all restorations were be evaluated by calibrated examiners following the fdi criteria

Eligibility criteria:
inclusion criteria: * patients should be over 18 years old. * patient should have good oral hygiene and general health * with at least 2 non-cavitated initial occlusal carious lesion first and/or second molar teeth in each quadrant of maxilla or mandible exclusion criteria: * known allergy to any of the resins used, * clinically detectable caries, * previously placed sealants or restorations, * bruxism or malocclusion
phase ii trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer

Conditions: Breast Cancer

Summary: this neoadjuvant chemotherapy protocol focusing on "triple-negative" breast cancers alone will gather a foundation of primary tumor and axillary lymph nodal response to primary chemotherapy and ongoing correlated disease-free (dfs) and overall survival (os) outcome data. this comparative data can then be used in building subsequent trials.

women with a diagnosed "triple-negative" proxy of basal-like breast cancer confirmed on a core biopsy and larger than 2 cm will be treated neoadjuvantly with the livingston metronomic regimen of 12 weeks of weekly doxorubicin 24 mg/m2 and daily oral cyclophosphamide 60 mg/m2 followed by 12 successive weeks of taxol 80 mg/m2 and carboplatin auc 2. although clinical response will be evaluated prior to surgery, the primary end-point is the pathologic response. secondary end-points will be dfs and os based upon standard of care surveillance. a pathologic complete response (pcr) will require no histologic evidence of residual malignant cells seen in the primary tumor area specimen or the lymph nodes. standard of care surgery and radiation therapy will be undertaken.

Eligibility criteria:
inclusion criteria: * women with estrogen receptor (er), progesterone receptor (pr),and her2 negative invasive breast cancer confirmed on core biopsy.(note: her2 negative by fish preferred; her2 0 or 1+ by ihc acceptable) * primary tumor size 2cm or greater by physical exam or radiographic measurements.(note: locally advanced t4 or inflammatory breast cancer is eligible.) * assessment of pre-treatment axillary lymph nodal status (note: fna biopsy if palpable or sentinel lymph node biopsy (slnb) if not palpable preferred; clinical exam acceptable.) * absolute neutrophil count \> 1500 mm3 and platelet count \> 100,000 mm3 * normal myocardial left ventricular function * serum creatinine \< 2.0 mg/dl * total bilirubin and ast \< 3x upper limits normal exclusion criteria: * recurrent or metastatic breast cancer findings (note: if oncologically felt to be a second breast primary, patient eligible for this protocol) * another active cancer present * medical contraindications to chemotherapy or surgery * first trimester pregnancy * breast feeding

Keywords: triple negative (er/pr negative; her2 negative)
efficacy & safety of quetiapine fumarate (seroquel) & placebo in the treatment of acutely ill patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.


Eligibility criteria:
inclusion criteria: * patient is able to provide written informed consent before beginning any study related procedures * patient has a documented clinical diagnosis of schizophrenia * patient is able to understand and comply with the requirements of the study, as judged by a study investigator exclusion criteria: * patients with a history of non-compliance as judged by the study investigator * patients with a known lack of response to previous treatment with quetiapine * patients who have participated in another drug study within 4 weeks prior to enrollment into this study * patients who have previously participated in this study or study d1444c00132

Keywords: schizophrenia schizophrenic disorder